Clinical strategies for the primary health care professional to minimize prescription opioid abuse

Postgraduate Medicine

Volumn 124, Issue 3, 2012, Pages 131-138

  Gudin, Jeffrey A ^a  

^a ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Abuse; Chronic pain; Misuse; Opioid; Prevention; Primary care

Indexed keywords

HYDROMORPHONE; MORPHINE SULFATE; MORPHINE SULFATE PLUS NALTREXONE; NALTREXONE; NARCOTIC ANALGESIC AGENT; OXYCODONE;

ARTICLE; BEHAVIOR DISORDER; CHRONIC PAIN; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; HEALTH CARE PERSONNEL; HUMAN; MORBIDITY; MORTALITY; OPIATE ADDICTION; PATIENT MONITORING; PATIENT REFERRAL; PATIENT SELECTION; PRESCRIPTION; PRIMARY HEALTH CARE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SKILL; UNITED STATES; CLINICAL PRACTICE; PAIN; REVIEW; RISK FACTOR;

ANALGESICS, OPIOID; HUMANS; OPIOID-RELATED DISORDERS; PAIN; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; REFERRAL AND CONSULTATION; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84867846862     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.05.2556     Document Type: Article

References (71)

1. US Department of Health and Human Services. SAMHSA. Office of Applied Studies. Results from the 2009 National Survey on Drug Use and Health: National Findings. Volume 1. Summary of National Findings. http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9results.htm. Accessed April 1, 2012.
2. Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
3. Katz NP, Birnbaum HG, Castor A. Volume of prescription opioids used nonmedically in the United States. J Pain Palliat Care Pharmacother. 2010;24(2):141-144.
4. Governale L. Outpatient presciption opioid utilization in the US, years 2000-2009. US Food and Drug Administration. http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ DrugSafetyandRiskManagementADvisoryCommittee/UCM220950. pdf. Accessed June 27, 2011.
5. Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain. 2004;109(3):514-519.
6. Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J Pain. 2006;7(4):225-235.
7. American Academy of Pain Medicine, the American Pain Society and the American Society of Addiction Medicine. Definitions related to the use of opioids for the treatment of pain. WMJ. 2001;100(5):28-29.
8. Katz NP, Birnbaum HG, Castor A. Volume of prescription opioids used nonmedically in the United States. J Pain Palliat Care Pharmacother. 2010;24(2):141-144.
9. US Government Accountability Office. Prescription pain reliever abuse: agencies have begun coordinating education efforts, but need to assess effectiveness. December 2011. http://www.gao.gov/products/GAO-12-115. Accessed March 19, 2012. Publication No. GAO-12-115.
10. Portenoy RK. Opioid therapy for chronic nonmalignant pain: current status. In: Fields HL, Liebeskind JC, eds. Progress in Pain Research and Management. Vol 1. Pharmacological approaches to the treatment of chronic pain: new concepts and critical issues. Seattle, WA: IASP Publications; 1994:247-287.
11. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8(7):573-582.
12. Fleming MF, Davis J, Passik SD. Reported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients. Pain Med. 2008;9(8):1098-1106.
13. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage. 1996;11(4):203-217.
14. Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006;7(9):671-681.
15. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360-372.
16. Reid MC, Engles-Horton LL, Weber MB, Kerns RD, Rogers EL, O'Connor PG. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med. 2002;17(3):173-179.
17. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432-442.
18. Manchikanti L, Giordano J, Boswell MV Fellows B, Manchukonda R, Pampati V Psychological factors as predictors of opioid abuse and illicit drug use in chronic pain patients. J Opioid Manag. 2007;3(2):89-100.
19. Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain. 2007;23(4):307-315.
20. Boyd CJ, McCabe SE, Cranford JA, Young A. Adolescents' motivations to abuse prescription medications. Pediatrics. 2006;118(6):2472-2480.
21. McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav. 2007;32(3):562-575.
22. Nwokeji ED, Rascati KL, Brown CM, Eisenberg A. Influences of attitudes on family physicians' willingness to prescribe long-acting opioid analgesics for patients with chronic nonmalignant pain. Clin Ther. 2007;29(suppl):2589-2602.
23. Potter M, Schafer S, Gonzalez-Mendez E, et al. Opioids for chronic nonmalignant pain. Attitudes and practices of primary care physicians in the UCSF/Stanford Collaborative Research Network. University of California, San Francisco. J Fam Pract. 2001;50(2):145-151.
24. Morley-Forster PK, Clark AJ, Speechley M, Moulin DE. Attitudes toward opioid use for chronic pain. Pain Res Manag. 2003;8(4):189-194.
25. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107-112.
26. Fine PG, Mahajan G, McPherson ML. Long-acting opioids and short-acting opioids: appropriate use in chronic pain management. Pain Med. 2009;10(suppl 2):S79-S88.
27. Smith H, Fine P, Passik S. Opioid Risk Management: Tools and Tips. Oxford University Press, Inc.; 2009.
28. Parsells Kelly J, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138(3):507-513.
29. Fanciullo GJ, Washington T. Best practices to reduce the risk of drug-drug interactions: opportunities for managed care. Am J Manage Care. 2011;17(suppl 11):S299-S304.
30. Pergolizzi JV, Quantifying the impact of drug-drug interactions associated with opioids. Am J Manage Care. 2011;17(suppl 11):S288-S292.
31. Butler SF, Budman SH, Fernandez KC, Fanciullo GJ, Jamison RN. Cross-Validation of a Screener to Predict Opioid Misuse in Chronic Pain Patients (SOAPP-R). J Addict Med. 2009;3(2):66-73.
32. Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the Current Opioid Misuse Measure. Pain. 2007;130(1-2):144-156.
33. McCarberg BH. Pain management in primary care: strategies to mitigate opioid misuse, abuse, and diversion. Postgrad Med. 2011; 123(2):119-130.
34. Passik SD, Weinreb HJ. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther. 2000;17(2):70-83.
35. Meltzer EC, Rybin D, Saitz R, et al. Identifying prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid Misuse Measure (COMM). Pain. 2011;152(2):397-402.
36. Reisfield GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci. 2007;37(4):301-314.
37. Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manage. 2004;27(3):260-267.
38. McCarberg BH. A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management. Postgrad Med. 2011;123(6):124-131.
39. Donovan MI, Evers K, Jacobs P, Mandleblatt S. When there is no benchmark: designing a primary care-based chronic pain management program from the scientific basis up. J Pain Symptom Manage. 1999;18(1):38-48.
40. Fishman SM, Bandman TB, Edwards A, Borsook D. The opioid contract in the management of chronic pain. J Pain Symptom Manage. 1999;18(1):27-37.
41. Hariharan J, Lamb GC, Neuner JM. Long-term opioid contract use for chronic pain management in primary care practice. A five year experience. J Gen Intern Med. 2007;22(4):485-490.
42. Wiedemer NL, Harden PS, Arndt IO, Gallagher RM. The opioid renewal clinic: a primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Med. 2007;8(7):573-584.
43. Alliance of States with Prescription Monitoring Programs. About the Alliance. http://www.pmpalliance.org/content/about-alliance. Accessed September 12, 2011.
44. Alliance of States with Prescription Monitoring Programs. Guidelines. Prescription Monitoring Program Goals. http://wwwpmpalliance. org/pdfs/resourcespdfs/goalsprescripmonitor.pdf. Accessed August 12, 2011.
45. Alliance of States with Prescription Monitoring Programs. Resources. http://www.pmpalliance.org/pdf/pmp_memb_list_2011_b.pdf. Accessed September 12, 2011.
46. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315-1321.
47. Elliott JA, Horton E, Fibuch EE. The endocrine effects of long-term oral opioid thearpy: a case report and review of the literature. J Opioid Manag. 2011;7(2):145-154.
48. Angst MS, Clark JK. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104:570-587.
49. Roy S, Loh HH. Effects of opioids on the immune system. Neurochem Res. 1996;21(11):1375-1386.
50. Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry. 2007;164(11):1750-1756.
51. Hays LR. A profile of OxyContin addiction. J Addict Dis. 2004; 23(4):1-9.
52. Setnik B, Roland CL, Cleveland JM, Webster L. The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med. 2011;12(4):618-631.
53. Shram MJ, Sathyan G, Khanna S, et al. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol. 2010;30(1):25-33.
54. Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20(2):5-13.
55. Exalgo (hydromorphone HCl) extended-release tablets [package insert]. Hazelwood, MO: Mallinckrodt Inc.; 2010.
56. OxyContin (oxycodone hydrochloride controlled-release) tablets CII [package insert]. Stamford, CT: Purdue Pharma L.P.; 2010.
57. Avinza (morphine sulfate extended-release capsules) [package insert]. Bristol, TN: King Pharmaceuticals, Inc.; 2008.
58. Opana ER (oxymorphone hydrochloride) extended-release tablets [package insert]. Chadds Ford, PA: Endo Pharmaceuticals, Inc.; 2008.
59. Kadian (morphine sulfate extended-release) capsules [package insert]. Morristown, NJ: Actavis Elizabeth LLC; 2010.
60. MS Contin (morphine sulfate controlled-release) tablets [package insert]. Stamford, CT: Purdue Pharma L.P.; 2009.
61. Oramorph SR (morphine sulfate) sustained release tablets [package insert]. Newport, KY: Xanodyne Pharmaceuticals, Inc.; 2006.
62. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10:11-18.
63. Embeda (morphine sulfate and naltrexone hydrochloride) [package insert]. Bristol, TN: King Pharmaceuticals; 2009.
64. US Food and Drug Administration. OxyContin-Questions and Answers. 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug-SafetyInformationforPatientsandProviders/ucm207196.htm. Accessed September 12, 2011.
65. Pande P, Hines J, Brogan A. Tamper-resistant properties of once-daily hydromorphone ER (OROS Hydromorphone ER). Poster presented at the American Pain Society 30th Annual Scientific Meeting, May 19-21, 2011, Austin, TX. Poster presentation: 331.
66. Cassidy TA, Coplan P, Black RA, Chilcoat H, Budman SH, Butler SF. Initial findings on abuse rates and routes of administration following introduction of reformulated OxyContin® (oxycodone HCL controlled-release) Tablets in a sentinel surveillance system of patients in substance use treatment. Presented at PAINWeek 2011, September 7-10, 2011; Las Vegas, NV
67. Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs. 2010;70(13):1657-1675.
68. Office of National Drug Control Policy. Epidemic responding to America's prescription drug abuse crisis. http://www.whitehousedrugpolicy.gov/publications/pdf/rxabuseplan.pdf. Accessed July 25, 2011.
69. US Food and Drug Administration. Post-Approval REMS Notification Letter. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM251595.pdf. Accessed July 29, 2011.
70. US Food and Drug Administration. Questions and answers: FDA requires a risk evaluation and mitigation strategy (REMS) for long-acting and extended-release opioids. http://www.fda.gov/Drugs/ DrugSafety/InformationbyDrugClass/ucm251752.htm. Accessed July 29, 2011.
71. US Food and Drug Administration. Medication Disposal: Questions and Answers. http://www.fda.gov/Drugs/ResourcesForYou/ Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/ SafeDisposalofMedicines/ucm186188.htm. Accessed August 12, 2011.